Akeso, Inc. (HK:9926)
:9926
Want to see HK:9926 full AI Analyst Report?
Top Page
Akeso, Inc.
(9926)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$82.00
▼(-45.70% Downside)
Action:Reiterated
Date:06/03/26
The score is held down primarily by elevated cash burn and recent losses (despite strong revenue growth and high gross margins), alongside bearish technical momentum with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend yield.
Positive Factors
Gross Margins
Sustained mid-to-high 70% gross margins reflect durable product-level pricing power and manufacturing economics for antibody biologics. High gross profitability supports reinvestment in R&D and commercialization, improving long-term scalability even if operating costs fluctuate.
Negative Factors
Negative Cash Flow / Cash Burn
Persistent negative operating and free cash flow indicate the business is consuming cash faster than it generates it, raising funding dependency. Over a multi-quarter horizon this elevates dilution or refinancing risk and can constrain capacity to support commercialization or late-stage trials without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margins
Sustained mid-to-high 70% gross margins reflect durable product-level pricing power and manufacturing economics for antibody biologics. High gross profitability supports reinvestment in R&D and commercialization, improving long-term scalability even if operating costs fluctuate.
Read all positive factors
Akeso, Inc. (9926) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$76.73B
Dividend YieldN/A
Average Volume (3M)11.45M
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth44.03%
EPS Growth-108.83%
CountryHK
Employees3,035
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.22
Shares Outstanding921,143,200
10 Day Avg. Volume8,237,327
30 Day Avg. Volume11,452,631
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)10.12
Price to Sales (P/S)30.78
P/FCF Ratio-50.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$178.06Price Target Upside17.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)<0.01
Revenue Forecast (FY)HK$5.02B
Akeso, Inc. Business Overview & Revenue Model
Company Description
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused t...
How the Company Makes Money
Akeso makes money primarily by commercializing its proprietary biologic drugs and by partnering its drug candidates with other pharmaceutical companies.
Key revenue streams include:
1) Product sales: Revenue from the sale of its approved and comm...
Akeso, Inc. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
63
Positive
Cash Flow
42
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.98B | 2.12B | 4.53B | 837.66M | 225.63M |
| Gross Profit | 2.34B | 1.83B | 4.39B | 734.54M | 195.41M |
| EBITDA | -663.11M | -604.99M | 2.17B | -1.27B | -1.32B |
| Net Income | -1.08B | -514.51M | 2.03B | -1.17B | -1.07B |
Balance Sheet | |||||
| Total Assets | 16.01B | 12.75B | 9.18B | 5.50B | 4.81B |
| Cash, Cash Equivalents and Short-Term Investments | 9.18B | 7.32B | 4.88B | 2.29B | 2.65B |
| Total Debt | 4.56B | 3.95B | 2.99B | 1.88B | 859.42M |
| Total Liabilities | 7.06B | 6.00B | 4.66B | 2.95B | 1.53B |
| Stockholders Equity | 9.05B | 6.81B | 4.69B | 2.64B | 3.16B |
Cash Flow | |||||
| Free Cash Flow | -1.83B | -1.11B | 1.59B | -2.02B | -1.71B |
| Operating Cash Flow | -1.11B | -527.62M | 2.47B | -1.24B | -1.00B |
| Investing Cash Flow | -4.17B | -1.52B | -4.00B | -889.75M | -579.59M |
| Financing Cash Flow | 3.72B | 3.39B | 960.89M | 1.49B | 1.59B |
Akeso, Inc. Technical Analysis
Negative
151.00
Price Trends
115.27
Negative
114.66
Negative
119.06
Negative
Market Momentum
-8.61
Negative
32.81
Neutral
35.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9926, the sentiment is Negative. The current price of 151 is above the 20-day moving average (MA) of 92.79, above the 50-day MA of 115.27, and above the 200-day MA of 119.06, indicating a bearish trend. The MACD of -8.61 indicates Negative momentum. The RSI at 32.81 is Neutral, neither overbought nor oversold. The STOCH value of 35.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9926.
Akeso, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$130.63B | 130.89 | 4.82% | ― | 38.55% | ― | |
61 Neutral | HK$30.26B | 31.66 | 23.99% | ― | 16.65% | 0.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$60.54B | 49.56 | 42.27% | ― | 80.08% | ― | |
47 Neutral | HK$15.80B | -10.79 | -24.29% | ― | 8.50% | 35.24% | |
46 Neutral | HK$76.73B | -59.21 | -14.26% | ― | 44.03% | -108.83% | |
42 Neutral | HK$30.17B | -45.66 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:9926
Akeso, Inc.
83.30
-8.65
-9.41%
HK:1801
Innovent Biologics
75.15
-3.25
-4.15%
HK:9688
Zai Lab Ltd
13.91
-13.54
-49.33%
HK:9995
RemeGen Co. Ltd. Class H
69.65
15.20
27.92%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.37
-5.38
-25.93%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
55.50
2.70
5.11%
Akeso, Inc. Corporate Events
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
Jun 12, 2026
Akeso has secured approval from China’s National Medical Products Administration for gumokimab, branded 奇佑康, for treating moderate-to-severe plaque psoriasis, following a pivotal Phase III study and three supportive tria...
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
Jun 11, 2026
Akeso, Inc. has authorized the use of up to HK$200 million of its existing cash resources to purchase its own shares on the open market through the trustee of its 2021 restricted share unit scheme, arguing that the current share price undervalues ...
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
Jun 5, 2026
Akeso, Inc. is a Cayman Islands–incorporated company listed in Hong Kong, operating in the healthcare and biopharmaceutical sector. The company is governed by a board comprising executive and non-executive directors and engages external audi...
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
May 31, 2026
Akeso highlighted its growing oncology portfolio with more than 40 clinical studies presented at the 2026 American Society of Clinical Oncology Annual Meeting, underscoring the breadth of its bispecific antibody strategy. The data centered on lead...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.